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Abstract 
Based on the reduction of permanganate by furosemide (FUR) in either acidic or basic 
medium, two simple, sensitive and cost-effective methods were proposed for the determination 
of FUR in bulk drug and in formulations. In method A, FUR was treated with a measured excess 
of permanganate in acid medium and the unreacted oxidant was measured at 550 nm, whereas 
in method B the reaction was carried out in alkaline medium and the resulting manganate was 
measured at 610 nm. In method A, the amount of permanganate reacted corresponds to the 
FUR content and the absorbance was found to decrease linearly with the concentration; while in 
method B, the absorbance increases with concentration. Under optimum conditions, working 
ranges was 3.0-24.0 µg ml-1 and 1.25-20.0 µg ml-1 by method A and method B, respectively. The 
calculated molar absorptivities are 9.06 × 103 and 1.36 × 104 L mol-1 cm-1 for method A and 
method B, respectively, with corresponding Sandell sensitivity values of 0.0365 and 0.0243 µg 
cm-2. The limits of detection (LOD) and quantification (LOQ) have also been reported. Accuracy 
and precision for the assay were determined by calculating the intra-day and inter-day at three 
concentration levels; the intra-day RSD was < 2.7% and the accuracy was better than 2.8% 
(RE). The methods were successfully applied to the determination of FUR in tablets and 
injections dosage forms; either in monopreparations of FUR or in combination with amiloride 
HCl. The results tallied well with the label claim and were statistically compared with those of a 
reference method by applying the Student’s t-test and F-test. The accuracy was further 
ascertained from placebo and synthetic mixture analysis and also from spike-recovery method. 
Keywords: Furosemide determination; Spectrophotometry; Potassium 
permanganate; Tablets.  
Introduction 
Furosemide (FUR), chemically known as 5-(aminosulfonyl)-4-chloro-2-[(2-
furanylmethyl) amino] benzoic acid, is structurally a sulfonamide, an antibacterial agent 
(Figure 1). However, FUR is a potent diuretic widely used in the treatment of 
edematous states associated with cardiac chronic renal failure [1,2], hypertension, 
congestive heart failure [3,4], and cirrhosis of the liver [5]. The official methods for the 
determination of FUR in dosage forms are based on titrimetry [6], spectrophotometry [7] 
and HPLC [8]. Besides, there are number of other techniques available in the literature 
and include, derivative UV spectrophotometry [9], spectrofluoremetry [10-12], HPLC with 
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UV detection [13], HPLC with fluorescence detection [14, 15], HPLC with amperometric 
detection [16], HPLC-DAD [17], LC-MS [18], GC-MS [19], micellar-LC [20], ratio-spectra 
derivative spectroscopy [21] and diffuse reflectance spectroscopy [22]., Because of its 
inherent simplicity, sensitivity and cost-effectiveness, visible spectrophotometry is a 
technique of choice employed in quality control laboratories of many developing 
countries. Therefore, developing a selective and sensitive methods using visible 
spectrophotometry is of paramount importance. Quite a few visible spectrophotmetric 
methods [23-34] have been developed for the quantification of FUR in pharmaceuticals 
which suffer from one or more disadvantage such as critical optimum conditions, 
heating and/or extraction step, narrow linear dynamic range and/or low sensitivity and 
poor selectivity. Reactions proposed for the visible spectrophotometric determination of 
FUR includes-reaction between FUR and FeCl3 in pH range 5.2-6.2 (λmax=513 nm)[23], 
FUR and Cu(II) at pH 3.2 using Mclivaine buffer (λmax=790 nm)[24], flow injection 
analysis based on reduction of KMnO4[25], complexation reaction with Fe(III) in 
ethanolic medium (λmax=513 nm)[26], unreacted Br2 measured after reacting with FUR 
(λmax= 520 nm)[27], reaction between FUR and 1, 2-napthaquinone-4-sulphonate at pH 
7.5 on heating for 30 min at 70 0C and extracted into isoamyl alcohol[28], FUR-Pd (II) 
complex at pH 5.0 at 55 0C (λmax=410 nm)[29], FUR-iron (III) complex (λmax=386 nm)[30], 
diazotization reaction[31], reaction with MBTH in the presence of various oxidizing 
agents[32], based on the reduction of  paramolybdate anoin or molybdatophosphoric 
anion (λmax=690 nm and 700 nm)[33], reaction between FUR and p-N,N-
dimethylphenylenediamine dihydrochloride in the presence of chloramie-T (λmax=540 
nm)[34]. 
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Figure 1: Structure of furosemide 
The present paper describes two visible spectrophotometric methods based on 
the reduction of KMnO4 in acid and basic mediums. Simplicity, sensitivity, wide linear 
ranges, mild experimental conditions and above all cost-effectiveness characterize the 
proposed methods. Further, the methods were found to possess adequate accuracy 
and precision. 
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Figure 2: Tentative reaction scheme for method A and method B. 
 
Experimental 
Apparatus 
A Systronics model 106 digital spectrophotometric with 1-cm matched quartz 
cells was used for all absorbance measurements. 
Reagents and Standards 
All chemicals used were of analytical reagent grade and distilled water was used 
to prepare all solutions. Potassium permanganate (1×10-2 M) was prepared by 
dissolving 0.395 g of the chemical (Merck, Mumbai, India) in water, the solution was 
boiled for 10 min to remove any residual manganese (IV) ions, cooled, filtered and 
diluted to 250 ml and standardized using H.A Bright’s procedure [35]. It was diluted to 
get 500 µg ml-1 for method A and 2 mg ml-1 for method B. Acetic acid (3:2, v/v) was 
prepared by diluting glacial acetic acid (Merck, Mumbai, India, Sp. gr. 1.05) 
appropriately with water. Sodium hydroxide solution (0.1 N) was prepared by 
dissolving the chemical (Merck, Mumbai, India) in water. Pharmaceutical grade FUR, 
certified to be 99.85% pure, was kindly provided by Hoechest Morrison Roussel Ltd., 
Mumbai, India, as gift and was used as received. For method A, 60 µg ml-1 FUR was 
prepared by dissolving 15.0 mg of FUR in 3:2 acetic acid and made up to 250 ml with 
the same acid. While for method B, 50 µg ml-1 FUR was prepared by dissolving 12.5 
mg of FUR in 0.1 N NaOH and made up to 250 ml with 0.1 N NaOH. Tablets and 
injections containing FUR alone or in combination with amiloride HCl were purchased 
from local market. 
Method A 
Different aliquots of standard solution (0.5-4.0 ml, 60 µg ml-1) of pure FUR 
prepared in acetic acid were transferred into a series of 10 ml volumetric flasks by 
means of micro burette and the total volume was adjusted to 4.0 ml with 3:2 acetic 
acid. To each flask, 1 ml of 5 M H2SO4 was added followed by 1 ml of 500 µg ml-1 
KMnO4, the latter being measured accurately. The flasks were kept aside for 10 min 
with occasional shaking before diluting to the mark with water. The absorbance was 
recorded at 550 nm against water blank. 
Method B 
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Into a series of 10 ml volumetric flasks, 0.25-4.0 ml of 50 µg ml-1 pure FUR 
solution made in NaOH were added by means of micro burette and the total volume 
was made up to 4.0 ml with 0.1 N NaOH. To each flask, 1 ml of 2 mg ml-1 KMnO4 
solution was added. The flasks were kept aside for 15 min with occasional shaking and 
the volume was made up to the mark with water. The absorbance was recorded at 610 
nm against the reagent blank. 
Procedure for Tablets/Injection/Combination tablets 
Twenty tablets containing FUR alone or twenty tablets containing FUR in 
combination with amiloride HCl were separately weighed and ground into fine powder 
(and preserved separately in two amber-colored bottles). An amount of either powder 
equivalent to 30 mg of FUR was weighed into a 50 ml volumetric flask, 30 ml of glacial 
acetic acid was added and the mixture was shaken for 20 min; the volume was then 
made up to the mark with water, mixed well and filtered using Whatman No. 42 filter 
paper. The filtrate equivalent to 600 µg ml-1 FUR was diluted to 60 µg ml-1 
concentration and a convenient aliquot was subjected to analysis using the procedure 
described under method A. Another portion of either tablet powder equivalent to 25 mg 
of FUR was weighed into a 50 ml volumetric flask, 30 ml of acetone was added and 
the mixture was shaken for 5 min. The mixture was filtered using Whatman No. 42 filter 
paper and the filtrate was evaporated to dryness on a water bath. The residue was 
washed thoroughly several times with water before dissolving it in 0.1 N NaOH. The 
solution was then transferred into a 50 ml volumetric flask, made up to the mark with 
0.1 N NaOH and suitable aliquot was then subjected to analysis using the procedure 
described under method B, after diluting to 50 µg ml-1 solution. Contents of twenty 
ampoules each containing 10 mg of FUR were pooled and mixed to get a 
homogeneous solution. An aliquot equivalent to 60 mg of FUR was accurately 
measured and transferred into previously dried 100 ml calibration flasks and made up 
to the mark with (3:2) acetic acid for use in method A. The solutions were diluted 
appropriately to achieve working concentration of 60 µg ml-1 FUR for method A and 
analyzed using the procedures described earlier. Analysis of FUR in injection by 
method B was unsuccessful since some diluents which were present interfered 
seriously with the analysis procedure and could not be removed by extraction with 
acetone.   
Results and Discussions 
Although permanganate is a strong oxidizing agent that can react with several 
organic substances, the tablet excipients in the analyzed samples did not interfere in 
case of method A and the interference due to excipients in the case of method B was 
successfully overcome by extraction with acetone. Recently, permanganate was 
studied to determine pharmaceutical active compounds in formulations both in acidic 
medium [12, 36] as well as in alkaline medium [37-40]. The titration of FUR (2.0-9.0 mg) 
against 0.03 M KMnO4 in 5 mL of 5M H2SO4 medium followed a 1:4 reaction 
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stiochiometry (FUR: KMnO4) (The work has been communicated to Proceedings 
National Academy of Science, New Delhi, India).  The studies of Drummond and 
Waters [41] showed that the reduction of permanaganate involves one electron change 
in alkaline medium forming bluish green manganate, which served as the chromogen 
for assay in method B.  
Optimisation of Experimental Conditions 
In method A, when a fixed concentration of permanganate was reacted with 
increasing concentrations of FUR in H2SO4 acid medium, a concomitant fall in the 
concentration of permanganate occurred as revealed by the decreasing absorbance at 
550 nm (Figure 3 & Figure 4), which served as the basis for quantification. A 
preliminary experiment showed that permanganate can be determined up to 50 µg ml-1 
(Figure 5) at 550 nm under the optimum acidic conditions of assay. Hence, different 
concentrations of FUR were reacted with 1 ml of 500 µg ml-1 KMnO4 to determine the 
concentration range over which FUR could be determined. To check the effect of acid 
concentration on the reaction, 0-5 ml of 5 M H2SO4 was added to the fixed 
concentration of FUR and KMnO4. It was observed that there was absolutely no 
change in the absorbance when 1-5 ml of 5 M H2SO4 were used in a total volume of 10 
ml. Effect of hydrochloric acid was not studied since KMnO4 being a strong oxidizing 
agent would react with HCl to liberate chlorine. The reaction between FUR and KMnO4 
in the acid concentration employed was complete in 10 min (Figure 6), and the 
absorbance of the measured unreacted KMnO4 was found to be stable up to 40 min 
thereafter. Appreciable change in the absorbance after 40 min could be due to the 
slow reaction between excess MnO4- with relatively high concentration of Mn2+. Two 
blanks were prepared for the study. Blank-1: Consist of 4.0 ml of 3:2 acetic acid, 1 ml 
of 5M H2SO4 and 1 ml of 500 µg ml-1 KMnO4 in a total volume of 10 ml (adjusted by 
water). This shows maximum absorbance reading at 550 nm against water. Blank-2: 
Consist of 4.0 ml of 3:2 acetic acid and 1 ml of 5M H2SO4 in a total volume of 10 ml 
(adjusted by water) shows negligible absorbance reading. Hence, all readings are 
taken against water. 
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 Figure 3: Calibration graphs for method A and method B. 
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Figure 4: Absorption spectra for method A and method B 
Method A: (A.0.0; B.3.0; C.6.0; D.12.0; E.18.0; F.24.0 µg ml-1 FUR). 
Method B: (Bluish green color produced for 15 µg ml-1 FUR). 
Blank: Absorbance against water. 
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Figure 5: Linear relation between absorbance at 550 nm and KMnO4 in 0.5M H2SO4. 
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Figure 6: Effect of reaction time in method A and method B.   
Potassium permanganate quantitatively oxidizes FUR in the presence of NaOH 
in method B, resulting in the formation of bluish-green color of manganate ion which 
Method A Method B
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showed absorption peak at 610 nm (Figure 4) and served as the basis for the 
calibration graph (Figure 3). An increase in the concentration of KMnO4 could enhance 
sensitivity of the method but the blank absorbance also increased concomitantly. The 
effect of KMnO4 concentration on the sensitivity of the reaction (Figure 7) based on 
which the optimum concentration was fixed at 0.2 mg ml-1 (1 ml of 2 mg ml-1 in a total 
volume of 10 ml). The overall NaOH concentration employed (0.04 N) is not critical, 
since higher concentrations did not affect either the sensitivity or stability of the 
reaction product. The reaction was complete in 10 min (Figure 6) and the contact time 
is not critical and any delay up to 30 min had no effect on the absorbance. The 
absorbance of the measured color was constant for 50 min in the presence of 
unreacted KMnO4 and the reaction product. Reagent blank consists of 4.0 ml of 0.1 N 
NaOH and 1 ml of 2mg ml-1 KMnO4 in a total volume of 10 ml (adjusted by water). This 
shows absorbance reading of 0.15 against water. Hence, all readings were taken 
against reagent blank. 
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Figure 7: Effect of KMnO4 concentration in method B. 
 
Analytical data 
Calibration graphs for method A and method B are described by the regression 
equation: 
           Y = 0.0249 + 0.0244 X, for method A and  
           Y = 0.0243 + 0.0377 X, for method B 
(Where Y = absorbance of 1-cm layer of solution and X = concentration in  
µg ml-1). In method A, the different between the reagent blank absorbance and 
the sample absorbance was plotted vs the FUR concentration. The limits of 
detection (LOD) and quantitation (LOQ) calculated according to ICH guidelines 
[42] were 0.74, 0.36 and 2.25, 1.10, respectively for method A and method B. The 
significance of correlation coefficients in method A and method B was evaluated 
by calculating the t-values using the following formula [43]. 
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The calculated values were found to be 60.24 and 76.18 for method A and 
method B, respectively. Thus, it can be concluded that there is significant relationship 
between the concentration of FUR and the variables used in the development of 
regression equations. 
Method Validation 
Assay precision and accuracy 
The precision of the methods was calculated in terms of intermediate precision 
(intra-day and inter-day) [44]. Three different concentrations of FUR were analysed in 
seven replicates during the same day (intra-day precision) and five consecutive days 
(inter-day precision). The RSD (%) values of intra-day and inter-day studies showed 
that the precision was good (Table 1). The accuracy of an analytical method expresses 
the closeness between the reference value and the found value. Accuracy was 
evaluated as percentage relative error between the measured concentrations and 
nominal concentrations for FUR (Bias %). The results obtained are compiled in table 1 
and show that the accuracy is good.  
Table 1. Intra-day and Inter-day precision and accuracy evaluation 
Method 
FUR 
µg 
ml-1 
taken 
Intra-day
(n=7) 
Inter-day 
(n=5) 
FUR 
µg ml-1 
founda 
Precisionb Accuracyc 
FUR 
µg ml-1 
founda 
Precisionb Accuracyc 
A 
6.000 6.140 2.580 2.330 6.150 3.160 2.500 
12.00 11.72 2.660 -2.330 12.33 2.870 2.750 
18.00 17.82 1.960 -1.010 18.27 2.420 1.500 
B 
5.000 5.10 2.630 1.960 5.110 3.020 2.200 
10.00 10.19 2.180 1.900 10.25 2.360 2.500 
15.00 15.12 1.310 0.840 15.20 2.180 1.340 
a. Mean ± standard error, b. Relative standard deviation (%), c. Bias %: (found-taken/taken) x 100. 
 
Method Selectivity 
Method selectivity was evaluated by preparing a synthetic mixture and it was 
confirmed that the change in signal measured (absorbance) was caused only by the 
analyte. A synthetic mixture consisting of 20 mg sodium alginate, 30 mg magnesium 
stearate, 20 mg lactose, 20 mg acacia, 50 mg talc and 30 mg starch besides 20 mg of 
FUR was prepared and analysed after extraction into acetic acid in method A and into 
acetone in the case of method B as described under “procedure for 
tablets/injection/combination tablet”. The percent recoveries of FUR were 101 ± 0.86 
and 98.58 ± 0.63 for method A and method B, respectively. This confirms the 
selectivity of methods under the optimized conditions. 
Matrix effect 
Matrix effect was carried out in order to find the interference. A placebo blank 
consisting of 20 mg sodium alginate, 30 mg magnesium stearate, 20 mg lactose, 20 
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mg acacia, 50 mg talc and 30 mg starch but without FUR was prepared and analysed 
as described under “procedure for tablets/injection/combination tablet”. There was 
absolutely no interference from the placebo in method A but huge interference was 
encountered in method B. The interference from placebo mixture in method B was 
successfully overcome by extraction of FUR into acetone and performing the analysis 
as described under “Procedure for Tablets/Injection/Combination tablet”.  
Application to analysis of pharmaceutical formulations  
Method A doesn’t suffer from interference from the tablet excipients and results 
in Table 2 show close agreement between the results obtained by the proposed 
methods and the label claim. Method B entails extraction of FUR into acetone since 
there was some interference from the excipients when applied directly to the tablet 
extract in NaOH. The acetone was later evaporated and the residue was dissolved in 
NaOH after repeatedly washing with water and an appropriate working concentration 
of FUR was prepared and analyzed as given under “procedure for 
tablets/injection/combination tablet”. FUR in injection could be determined without 
interference using method A. However, interference due to co-formulated substances 
in injections could not be overcome in method B by simple extraction with acetone as 
done for tablets. The results were compared statistically by applying Student’s t-test for 
accuracy and variance ratio F-test for precision with those of the literature method [7] at 
95% confidence level. The literature method consisted of extraction of FUR from the 
matrices using 0.1N NaOH and detection at 271 nm. The calculated t-test and F-
values (Table 2) did not exceed the tabulated values of 2.78 and 6.39, respectively, 
indicating no significant difference between the proposed methods and the reference 
method in terms of accuracy and precision. The validity of the methods was confirmed 
by applying the standard addition technique. Pre-analyzed tablet powder containing 
FUR was spiked with pure FUR at three concentration levels and the total was 
measured by the proposed methods. Each determination was done three times. The 
results of this study are compiled in table 3.    
 
Table 2: Summary of furosemide assay results for different dosage forms 
                            
Tablets/Injection/ 
Combination tablet 
analyzed 
Label claim 
 
Found* (Percent of label claim ±SD) 
Reference 
method Method A Method B 
Frunexa 
(FUR alone) 100 mg/Tab 
95.84 ± 1.26 94.50 ± 2.48 
t= 1.13 
F=  3.87
96.12 ± 2.64 
t= 0.22 
F= 4.39
Lasixb 
(FUR alone) 40 mg/Tab 
99.32 ± 1.08 98.46 ± 2.32 
t= 0.79 
F= 4.61
101.10 ± 1.74 
t= 1.88 
F= 2.59
Lasixc 
(Injection) 10 mg/Ampoule 
101.9 ± 1.15 102.3 ± 1.42 
t= 0.49 
F= 1.52
 
------ 
Amifrud 
(Combination Tab) 40 mg/Tab 
104.0 ± 1.36 103.6 ± 2.58 
t= 0.32 
F= 3.59
103.9 ± 2.75 
t= 0.08 
F= 4.08 
 
*Mean value of five determinations 
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 Marketed by:  
aGeno Pharmaceuticals Ltd. Karaswada, Goa-403507 
bAventis Pharma Ltd. Ankleshwar-393002 
cAventis Pharma Ltd. Thane-401506 
d Elder Pharmaceuticals Pvt Ltd. Mumbai-400053 
Tabulated t-value at the 95% confidence level is 2.78; Tabulated F-value at the 95% confidence 
level is 6.39. 
Table 3: Results of recovery study by standard addition method 
Formulation 
studied 
Method A Method B 
FUR in 
tablet, 
µg 
ml-1 
Pure FUR 
added, 
µg ml-1 
 
Total 
found, µg 
ml-1 
 
Pure FUR 
recovered*, 
Percent ± SD 
FUR in 
tablet, 
µg ml-1 
 
Pure 
FUR 
added, 
µg ml-1
Total 
found, 
µg 
ml-1 
Pure FUR 
recovered*, 
Percent ± SD 
Lasix 40 mg 
7.880 4.000 11.77 97.25 ± 2.17 8.090 4.000 12.26 104.30 ± 1.85 
7.880 8.000 15.93 100.60 ± 1.78 8.090 8.000 16.59 106.2 ± 2.67 
7.880 12.00 20.28 103.30 ± 2.36 8.090 12.00 20.27 101.5 ± 2.19 
Amifru 
40 mg 
combination 
Tablet 
8.290 4.000 12.36 101.70 ± 1.62 8.310 4.000 12.32 100.3 ± 2.48 
8.290 8.000 16.81 106.50 ± 2.46 8.310 8.000 16.59 103.5 ± 1.84 
8.290 12.00 20.85 104.70 ± 2.75 8.310 12.00 20.51 101.7 ± 2.34 
 
*Mean value of three determinations 
 
Conclusion 
The proposed two methods are free from rigid experimental conditions and are 
characterized by wide linear dynamic ranges and high sensitivity, and employ 
inexpensive and easily available chemicals and hence cost-effective when compared 
to the existing spectrophotometric methods. Method A is simpler and can be extended 
successfully to the quantification of FUR present in the injections and combination 
tablets without interference from the other active ingredients. However, method B 
entails an extraction step when applied to tablets to overcome the interference from 
some inactive ingredients. The low detection and quantification limits, simplicity and 
selectivity make the method suitable for the quality control in the pharmaceutical 
industry for routine analysis. 
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